The US government collected $4.7 billion from state-legal weed businesses in 2017, according to a report from Quartz.
Cannabis Industry
CVS and Walgreens to venture into cannabis industry
Your friendly neighborhood pharmacy also just became … your friendly neighborhood weed dealer?
Forecast: Massachusetts Goes Legal, On Pace For $2 BILLION Sales Market
Massachusetts’ marijuana legalization went into full effect this week. Judging by the data, this is going to add significantly...
California Marijuana Crackdown Is GREAT For California Marijuana Stocks
California is set for a major crackdown of illegal marijuana operations. Yes, they are illegal. But they’re also becoming increasingly dangerous.
Purified Cannabinoids Open New Opportunities in Pain Management
In Canada, chronic pain affects 1.5 million people. As national and worldwide numbers in pain diagnoses continue to rise, innovators in the cannabis industry are developing promising therapies to address this growing market.
India Globalization Capital, Inc. (NYSE: IGC) Enters MOU for Distribution in Germany, Plans to Commercialize Liquid Formulation of Hyalolex
India Globalization Capital, Inc. (NYSE American: IGC) sees opportunities in 2018, primarily from the distribution, in Germany, of its cannabinoid-based therapies, including IGC-AD1 (Hyalolex).
From CFN - Exclusive CEO Interview: InMed Pharmaceuticals’ Biosynthesis Platform Results in an Industry First
CFN Media sits down for an exclusive interview with InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). (VIDEO)
India Globalization Capital (NYSE: IGC) Avoids Regulatory Costs through Cannabis-based Drug Candidates
India Globalization Capital (NYSE AMERICAN: IGC) is developing a portfolio of products using cannabis-based “combination therapies” for the treatment of various life-altering conditions.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Unlocks Ability to Produce 90+ Cannabinoids through Biosynthesis
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues to advance its drug development programs through the use of its proprietary bioinformatics database assessment tool.
Rising Demand for Cannabis Oils Pushes Canada’s Producers into Overdrive
As one of Canada’s first licensed cannabis producers, ABcann is significantly ahead of the curve when it comes to production capacities.
Innovation Drives Value for Leading Cannabis Biotechs
As an increasing volume of scientific research leans toward the efficacy of cannabis-based drugs, innovative biotech companies are advancing their R&D to develop therapeutic candidates that envelop the potential health benefits of the marijuana plant.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Presenting at Cannabis-Based Science & Medicine Conference
InMed Pharmaceuticals this morning said that it will be presenting twice at the Biopharma Forum on ‘Cannabis-Based Science & Medicine’ conference.
Biosynthesis: Making the Impossible Possible in Medicinal Cannabis
InMed Pharmaceuticals, Inc. has broken new ground with an innovative, proprietary biosynthesis process that reliably creates pure cannabinoids.
Cannabis Biotechs Could be Big Pharma’s Latest M&A Focus
InMed’s promising biosynthesis platform could put it on the radar of some major names seeking entry into one the pharmaceutical industry’s fastest-growing sectors.
How InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Breakthrough Biosynthesis Works - Video
There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.